Ransford, R.A. and Langman, M.J. (2002) Sulphasalazine and Mesalazine: Serious Adverse Reactions Re-Evaluated on the Basis of Suspected Adverse Reaction Reports to the Committee on Safety of Medicines. Gut, 51, 536-539.
https://doi.org/10.1136/gut.51.4.536

has been cited by the following article:

• TITLE: Kidney Manifestations of Inflammatory Bowel Diseases

  AUTHORS: Kawthar Braysh, Alice Gerges Geagea, Charbel Matar, Manfredi Rizzo, Assaad Eid, Liliane Massaad-Massade, Samir Mallat, Abdo Jurjus

  KEYWORDS: IBD, Crohn’s Disease, Ulcerative Colitis, Inflammatory Cytokines, Kidney Diseases

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.8 No.5, May 30, 2018

  ABSTRACT: Inflammatory bowel disease (IBD) is profoundly associated with extraintestinal manifestations (EIM) that can involve almost every organ in our body. Although the exact etiology of IBD is still poorly understood, it is generally characterized by an overly aggressive inflammatory response in the intestinal mucosa. Renal damage is one of the manifestations encountered in Crohn’s disease (CD) and ulcerative colitis (UC) and it accounts for 4% - 23% of IBD patients. The common renal complications of IBD include: glomerulonephritis, tubulointerstitial nephritis, nephrolithiasis, amyloidosis and iatrogenic complications of IBD treatment. Several hypotheses have emerged to explain the pathogenic mechanisms underlying the prevalence of IBD-induced kidney injuries. The present work aims to elucidate the pathological principles that drive secondary renal injury in individuals with IBD and highlight the currently used therapeutic strategies for evaluating, monitoring and treating kidney complications-related IBD.